These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 26724654

  • 21. EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation.
    Li H, Guo Z, Si T, Wang H.
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):620-7. PubMed ID: 23325276
    [Abstract] [Full Text] [Related]

  • 22. Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
    Mulé S, Thiefin G, Costentin C, Durot C, Rahmouni A, Luciani A, Hoeffel C.
    Radiology; 2018 Aug; 288(2):445-455. PubMed ID: 29584597
    [Abstract] [Full Text] [Related]

  • 23. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.
    Kim MN, Kim BK, Han KH, Kim SU.
    Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):335-48. PubMed ID: 25370168
    [Abstract] [Full Text] [Related]

  • 24. Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
    Lee FA, Zee BC, Cheung FY, Kwong P, Chiang CL, Leung KC, Siu SW, Lee C, Lai M, Kwok C, Chong M, Jolivet J, Tung S.
    Am J Clin Oncol; 2016 Dec; 39(6):609-613. PubMed ID: 24977690
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S, Corcuera-Solano I, Stueck A, Besa C, Argiriadi P, Guniganti P, King M, Kihira S, Babb J, Thung S, Taouli B.
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [Abstract] [Full Text] [Related]

  • 26. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
    Shim JH, Han S, Shin YM, Yu E, Park W, Kim KM, Lim YS, Lee HC.
    J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
    [Abstract] [Full Text] [Related]

  • 27. Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib.
    Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baek SE, Kim HS, Kim SU, Park MS.
    Liver Int; 2018 Sep; 38(9):1655-1663. PubMed ID: 29495116
    [Abstract] [Full Text] [Related]

  • 28. Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
    Maida M, Macaluso FS, Valenza F, Virdone R.
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):253-5. PubMed ID: 27308660
    [Abstract] [Full Text] [Related]

  • 29. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
    Kim MJ, Choi JI, Lee JS, Park JW.
    J Gastroenterol Hepatol; 2011 Jul; 26(7):1201-6. PubMed ID: 21371120
    [Abstract] [Full Text] [Related]

  • 30. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.
    Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T.
    J Hepatol; 2011 Dec; 55(6):1309-16. PubMed ID: 21703196
    [Abstract] [Full Text] [Related]

  • 31. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.
    Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ.
    Radiology; 2012 Feb; 262(2):708-18. PubMed ID: 22187634
    [Abstract] [Full Text] [Related]

  • 32. Comparison of RECIST, mRECIST, and choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads.
    Yeo DM, Choi JI, Lee YJ, Park MY, Chun HJ, Lee HG.
    J Comput Assist Tomogr; 2014 Feb; 38(3):391-7. PubMed ID: 24681857
    [Abstract] [Full Text] [Related]

  • 33. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.
    Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM.
    Eur Radiol; 2021 May; 31(5):2737-2746. PubMed ID: 33123796
    [Abstract] [Full Text] [Related]

  • 34. Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
    Arizumi T, Ueshima K, Takeda H, Osaki Y, Takita M, Inoue T, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.
    J Gastroenterol; 2014 Dec; 49(12):1578-87. PubMed ID: 24499826
    [Abstract] [Full Text] [Related]

  • 35. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.
    Dig Dis; 2014 Dec; 32(6):705-10. PubMed ID: 25376287
    [Abstract] [Full Text] [Related]

  • 36. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A, Huynh TJ, Rajan DK, Marquez MA, Grant DR, Huynh DC, Jaskolka JD.
    J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
    [Abstract] [Full Text] [Related]

  • 37. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
    Parikh ND, Marshall VD, Singal AG, Nathan H, Lok AS, Balkrishnan R, Shahinian V.
    Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
    [Abstract] [Full Text] [Related]

  • 38. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
    Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM.
    J Hepatol; 2017 Jun; 66(6):1166-1172. PubMed ID: 28131794
    [Abstract] [Full Text] [Related]

  • 39. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Ippolito D, Querques G, Pecorelli A, Talei Franzesi C, Okolicsanyi S, Strazzabosco M, Sironi S.
    J Comput Assist Tomogr; 2019 Jun; 43(2):206-213. PubMed ID: 30407241
    [Abstract] [Full Text] [Related]

  • 40. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
    Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E, Eng J, Kamel IR.
    Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.